OOIR: Observatory of International Research

Papers

(The H4-Index of Metabolism-Clinical and Experimental is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York	608
Obesity in patients with COVID-19: a systematic review and meta-analysis	323
Complications, morbidity and mortality of nonalcoholic fatty liver disease	272
A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on	271
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease	244
Insulin resistance, cardiovascular stiffening and cardiovascular disease	243
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses	242
MAFLD and risk of CKD	177
Commentary: Obesity: The “Achilles heel” for COVID-19?	158
Role of the gut microbiota in type 2 diabetes and related diseases	155
Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19	147
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease	139
The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany	138
The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis	134
Commentary: Testosterone, a key hormone in the context of COVID-19 pandemic	133
Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019	125
Commentary: COVID-19 in patients with diabetes	121
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk	105
Letter to the Editor: Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China	101
Metformin: Is it a drug for all reasons and diseases?	99
Visceral fat is associated to the severity of COVID-19	96
Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: A dose-response meta-analysis	95
The serum metabolome of COVID-19 patients is distinctive and predictive	92
Insulin resistance and insulin sensitizing agents	90
Metabolic liver disease in diabetes – From mechanisms to clinical trials	89

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis	89
Epidemiology of sarcopenia: Prevalence, risk factors, and consequences	88
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes	86
Heart failure in diabetes	85
Insulin: The master regulator of glucose metabolism	80
Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy	76
The effect of underweight on female and male reproduction	71
FUNDC1 insufficiency sensitizes high fat diet intake-induced cardiac remodeling and contractile anomaly through ACSL4-mediated ferroptosis	71
Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity	70
The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease	67
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression	65
The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis	64
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis	62
Mediterranean diet as a nutritional approach for COVID-19	62
Diabetes and COVID-19: The past, the present, and the future	61
Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next	61
Letter to the Editor: Vitamin D deficiency in COVID-19: Mixing up cause and consequence	59
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?	59
Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data	59
Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?	58
Impact of body composition on COVID-19 susceptibility and severity: A two-sample multivariable Mendelian randomization study	58
Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies	56
Factors affecting weight loss variability in obesity	52
The effect of excess body fat on female and male reproduction	51
FOS/GOS attenuates high-fat diet induced bone loss via reversing microbiota dysbiosis, high intestinal permeability and systemic inflammation in mice	51
A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage	50